Kornimate/medical-research-clean huggingface dataset:
peri-implant disease and prosthetic cement: cross-sectional study

Conditions: Peri-implant Mucositis; Peri-Implantitis

Summary: the main objective of the present clinical study project, of a cross-sectional observational nature, is to evaluate the presence of submucosal cement residues through endoscopic visualization in clinical situations with peri-implant disease. the secondary objective is to investigate the potential correlation between the severity of the pathological condition and the spatial position of cement residues in relation to the implant-prosthetic unit. for each subject, the following data were collected: gender, age, periodontal history, smoking habits, reasons for implant rehabilitation (trauma, caries, periodontitis, agenesis, other), the position of the implant in the oral cavity, elapsed time between prosthetic rehabilitation and pathological condition. if the deposit was recognized as cement residue, its presence was recorded, and the anatomical position of the cement residue (mesial, distal, lingual/palatal, vestibular) and the spatial position of cement residues in relation to the implant-prosthetic unit were collected.


Eligibility criteria:
inclusion criteria: * at least one single-implant with cemented restoration and clinical-radiographic signs of peri-implant disease * patients with previous periodontitis had to have a healthy but reduced periodontium exclusion criteria: * neuromotor pathologies or morphological-dysfunctional alterations

Keywords: dental implants peri-implant diseases excess cement implant prosthesis endoscopy
safety of overestimation of a meal insulin bolus in the context of dual-hormone closed-loop operation

Conditions: Type 1 Diabetes

Summary: in previous studies, investigators have studied if a pre-meal insulin bolus based on estimated carbohydrate meal size would alleviate the burden of carbohydrate counting without a significant degradation in postprandial glucose control. with this strategy, the patient would only have to evaluate the size of the meal in terms of carbohydrate (snack, regular, large or very large) it is however important to establish safety of this simplified meal bolus approach. the safety of overestimating a meal insulin bolus in the context of single and dual-hormone cls with the simplified meal strategy needs to be determined. computer simulation will be used to get a reasonable estimate of risks related to over-estimation with single-hormone closed-loop while over-estimation with dual-hormone closed-loop will be tested in adults with type 1 diabètes investigators hypothesize that dual-hormone closed-loop with overestimated meal size bolus will not increase time below 4.0 mmol/l compared to dual-hormone closed-loop with an adequately estimated meal size bolus


Eligibility criteria:
inclusion criteria: 1. males and females ≥ 18 years old. 2. clinical diagnosis of type 1 diabetes for at least one year. 3. the subject will have been on insulin pump therapy for at least 3 months and currently using a fast actin insulin analog (lispro, aspart or guilisine). 4. last (less than 3 months) hba1c ≤ 10%. 5. currently using carbohydrate counting as the meal insulin dose strategy. exclusion criteria: 1. clinically significant microvascular complications: nephropathy (estimated glomerular filtration rate below 40 ml/min), neuropathy (especially diagnosed gastroparesis) or severe proliferative retinopathy as judged by the investigator. 2. recent (\< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery. 3. pregnancy. 4. severe hypoglycemic episode within 1 month of screening. 5. agents affecting gastric emptying (motilium®, prandase®, victoza®, byetta® and symlin®) as well as oral anti-diabetic agents (metformin, sglt-2 inhibitors and dpp-4 inhibitors) if not at a stable dose for 3 months. otherwise, these medications are acceptable and will be kept stable during the entire protocol. 6. oral steroids unless patients present a low stable dose (e.g. 10 mg or less of prednisone per day or physiological doses, less than 35 mg/day, of hydrocortisone cortef®). inhale steroids at stable dose in the last month are acceptable. 7. other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator (e.g. unstable psychiatric condition). 8. failure to comply with team's recommendations (e.g. not willing to change pump parameters, follow algorithm's suggestions, etc).

Keywords: type 1 diabetes artificial pancreas closed-loop system postprandial glucose control hypoglycemia insulin glucagon
concomitant surgical atrial fibrillation ablation in double valve replacement

Conditions: Atrial Fibrillation; Valvular Heart Disease

Summary: current european society of cardiology guidelines recommend concomitant atrial fibrillation (af) ablation for all symptomatic patients undergoing other cardiac surgeries, but the safety and potential benefits of concomitant atrial fibrillation (af) ablation at the time of double valve replacement remains unexamined. a retrospective review of patients with af who underwent double valve replacement with or without concomitant surgical ablation in our institute starting from april 2006.

persistent af was defined as af lasting more than 7 days and long-standing persistent af as continuous af for more than 12 months. concomitant surgical af ablation was offered to suitable patients as determined by the surgeon, and patients then decided whether to undergo the additional procedure. the operations were performed through median sternotomy and under cardiopulmonary bypass. the bipolar ablation clamp was positioned precisely around the pulmonary veins (pv) for bilateral circular ablation. after marsh ligament cutting and cross-clamping the ascending aorta, the left atrial appendage was resected and left atrial cavity exposed through an incision behind the interatrial groove. then, linear ablations were performed between the left and right inferior pvs, between the left and right superior pvs, between the left superior pv and the opening of the left atrial appendage, and between the line connecting bilateral inferior pvs and the mitral valve isthmus. ablation at the right atrium was then performed. briefly, the bipolar ablation clamp was positioned around the inferior vena cava (ivc) and right atrial appendage for circular ablation. an l-shaped incision was then made on the anterior wall of the right atrium and linear ablations were performed vertically from the incision to the interatrial groove and tricuspid annulus, to the ablation ring around the right atrial appendage, and from the superior vena cava to the ablation ring around the inferior vena cava. the left atrial appendage was always excluded by resection and the incision was closed with continuous running stitches. temporary pacemakers were placed in all patients and activated when heart rate was less than 70 beats per minute.

Eligibility criteria:
inclusion criteria: * patients presented to our institute with valvular heart disease requiring double valve replacement and also present with persistent or long-standing persistent atrial fibrillation. * persistent af was defined as af lasting more than 7 days and long-standing persistent af as continuous af for more than 12 months. first cardiac surgery, age\ 40% exclusion criteria: * \>70 years old, with la diameter \>7 cm, or with lv ejection fraction \< 40% , repeated cardiac surgery, concomitant tricuspid valve replacement

Keywords: double valve replacement atrial fibrillation ablation
effects of tablet computer-based cognitive training in patients with idiopathic rem sleep behavior disorder

Conditions: REM Sleep Behavior Disorder

Summary: to evaluate the effectiveness of tablet computer-based cognitive training in patients with idiopathic rem sleep behavior disorder.

rapid eye movement (rem) sleep behavior disorder (rbd) is a parasomnia characterized by abnormal movement to reproduce dreams and loss of skeletal muscle tension during rem sleep. idiopathic rbd (irbd) refers to the absence of any predisposing factors or comorbid neurological disorders. irbd is considered the prodromal stage of alpha-synucleinopathy. through past studies, it has been confirmed that cognitive function decline has already occurred in a significant number of irbd patients. however, there is still no treatment that can suppress or delay the onset of neurodegenerative diseases. the cognitive function improvement effect of computerized cognitive training in the elderly and patients with mild cognitive impairment is known. however, the effect of cognitive training on improving cognitive function in irbd patients has not been studied. the investigators developed a program that allows patients to train cognitive functions in various domains by repeatedly performing tasks related to daily life activities. in addition, by loading the program on the tablet computer, it is possible to participate in the training easily at home using the touch screen without visiting the hospital.

Eligibility criteria:
inclusion criteria: * patients aged 60-80 years old who have been diagnosed with irbd through nocturnal polysomnography according to the international classification of sleep disorders 3rd edition (icsd-3) diagnostic criteria * those who gave their written consent to participate in the study exclusion criteria: * patients with neurodegenerative diseases including parkinson's disease, dementia, and multiple system atrophy * patients with secondary causes of rbd * patients with severe hearing, visual impairment, or motor impairment * patients who have received cognitive training within the last year
the study on the efficacy of tdcs stimulation of the cerebellum combined with xingnaojing injection in patients with consciousness disorders after cranial injury

Conditions: tDCS; Cerebellum; Brain Injury; Disturbance of Consciousness

Summary: the purpose of this study is to investigate the effect of tdcs stimulation of cerebellum combined with xingnaojing on patients with disturbance of consciousness after craniocerebral injury, and to clarify the relationship between the following two points: (1) to clarify whether mmn, p300, fnirs, baep, sep can be used as objective indicators to distinguish vs from mcs. (2) to clarify the changes of consciousness level and brain function in doc patients with craniocerebral injury treated with tdcs stimulation of cerebellum combined with xingnaojing.


Eligibility criteria:
inclusion criteria: 1. aged 18-80 years; 2. all patients met the diagnostic criteria of doc; 3. more than 1 month after the initial head injury; 4. stable consciousness for at least 2 weeks before admission (no change in crs-r total score); 5. no skull defect or large area of skull repair; 6. the legal representative authorized by the patient approved the experimental protocol and signed the informed consent form. exclusion criteria: 1. supratentorial abnormalities on computed tomography (ct) or magnetic resonance imaging (mri) involving more than one third of the middle cerebral artery territory; 2. a life expectancy of less than 3 months or a follow-up of less than 3 months; 3. retention of intracranial metal objects, cranial debridement, or presence of cranial defects and any clinically significant or unstable medical diseases; 4. eeg recording with significant muscle artifacts and inhibitory bursts; 5. nonconvulsive status epilepticus; periodic or burst rhythms evoked by stimulation; 6. disturbance of consciousness due to surgical injury or tumor.
refractory diffuse large b-cell lymphoma

Conditions: Diffuse Large B-cell Lymphoma

Summary: in the rituximab era, one-third of diffuse large b-cell lymphoma (dlbcl) patients experience relapse/refractory disease after first-line anthracycline-based immunochemotherapy (ichemo). optimal management remains an unmet medical need. the aim of this study was to report the outcomes of a cohort of refractory patients according to their patterns of refractoriness and the type of salvage option. the investigators performed a retrospective analysis, which included 104 dlbcl patients treated at lyon sud university hospital (2002-2017) who presented with refractory disease. the investigators retrospectively evaluated the outcomes of a cohort of 104 refractory patients according to their patterns of refractoriness and the type of salvage option.


Eligibility criteria:
inclusion criteria: -≥18 years of age * diagnosed with dlbcl at lyon sud university hospital (lsuh) from january 2002 to january 2017 * presented with refractory disease in response to front-line therapies * including anthracycline-based chemo and a monoclonal anti-cd20 antibody exclusion criteria: * patients with a history of indolent lymphoma, * patients with a primary central nervous system (cns) lymphoma or immunosuppression-related lymphoma

Keywords: diffuse large b-cell lymphoma refractory rituximab
genetic susceptibility to lung cancer in never smokers

Conditions: Lung Cancer

Summary: the purpose of this study is to help us better understand the cellular changes that may lead to the development of lung cancer. we want to compare people who have never smoked and yet have been diagnosed with lung cancer to never smokers who have not developed lung cancer. we hope to use the information obtained in this study as the basis for future studies and will not regard the results from this study as final.


Eligibility criteria:
inclusion criteria: * cases will be eligible for inclusion if: * they have been diagnosed with a lung cancer or have had previous surgical treatment for their lung cancer and have smoked fewer than 100 cigarettes in their lifetime, are/were not regular cigar or pipe smokers, and * they have had no prior chemotherapy or radiation treatment within the last year (exception: genotyping analysis/screening can be performed on specimens from individuals who had chemo/radiation treatment within the last year as germline dna will not be affected) * they speak and read english * they understand and agree to sign informed consent, and * they agree to give us a blood sample, and * they agree to complete the study questionnaire, and * they agree to have their pathology information reviewed by study personnel. * controls will be eligible for inclusion if: * they have not been diagnosed with any type of cancer, exclusive of nonmelanoma skin cancer and have smoked fewer than 100 cigarettes in their lifetime, are/were not regular cigar or pipe smokers, and * they speak and read english * they understand and agree to sign informed consent, and * they agree to give us a blood sample, and * they agree to complete the study questionnaire. exclusion criteria: * subjects who do not meet the inclusion criteria for either the case or control groups will not be eligible for this study. * all individuals who otherwise meet the eligibility requirements above, but who have had chemotherapy or radiation therapy within 1 year of evaluation will be excluded (exception: genotyping analysis/screening can be performed on specimens from individuals who had chemo/radiation treatment within the last year as germline dna will not be affected).

Keywords: smokers
lactoferrin versus total dose infusion (tdi) for treating iron deficiency anemia in pregnancy: role of nursing

Conditions: Iron Deficiency Anemia

Summary: this study consisted of 60 cases. all the cases of pregnant women are 4 months to 8 months of pregnancy. the cases divided into 30 pregnant women's were given iron supplementation without health education and another 30 were given iron supplementation and health education for comparison between them. comparative between hemoglobin levels before and after medication. treatment of iron deficiency anemia with iron supplementation received for one month.

the investigator will divide the participants into two groups e.g. group (a) and group (b) according to hemoglobin level and receiving of oral supplementation for ida accompanied with health education in case of group (a) and without health education in case of group (b). then the investigator asked patient to sign the document of her investigations result to receive iron supplementation. * after that, the investigator observes hemoglobin's level, when it less than \>11g/dl, the patient will be the group (a) who will receive oral iron supplementation and health education. * group (b) who will receive total dose infusion (tdi) without health education.

Eligibility criteria:
inclusion criteria: 1. pregnant women aged \>18 years 2. hemoglobin\<10g/dl 3. gestational age between 14-28 weeks 4. singleton pregnancy 5. willingness to participate and signing the informed consent form exclusion criteria: 1. anemia predominantly caused by factors other than ida (e.g. anemia with untreated b12 or foliate deficiency, hemolytic anemia), 2. iron overload or disturbances in utilization of iron (e.g. hemochromatosis and haemosidrosis). 3. decompensated liver cirrhosis and active hepatitis (alat\>3 times upper limit of normal). 4. active acute or chronic infections (assessed by clinical judgment supplied with white blood cells (wbc) and c - reactive protein (crp). 5. rheumatoid arthritis with symptoms or signs of active inflammation. 6. multiple allergies. 7. known hypersensitivity to parental iron or any recipients in the investigational drug products. 8. erythropoietin treatment within 8 weeks prior to the screening visit. 9. other iron treatment within 8 weeks prior to the screening visit. 10. planned elective surgery during the study. 11. participation in any other clinical within 3 months prior to the screening. 12. any other medical condition e.g. malignancy, uncontrolled hypertension, unstable ischemic heart disease, or uncontrolled diabetes mellitus.
fast versus slow tenaculum placement

Conditions: IUD Insertion Complication; Endometrial Diseases

Summary: the purpose of the study is to investigate whether the speed of tenaculum placement affects perceived patient pain during office transcervical procedures.

iud insertion and endometrial biopsies are commonly performed in office procedures that use a tenaculum to stabilize the cervix. patient's often complain that tenaculum placement is one of the most uncomfortable parts of these procedures. patient's who agree to be in the study will be randomized into one of two groups, either slow tenaculum placement or fast tenaculum placement. throughout the procedure patient's will be asked to rate the amount of pain they are experiencing using a visual analog scale. the researchers will then compare the two groups. the providers will also rate what they perceived the patient's pain to be with the procedure.

Eligibility criteria:
inclusion criteria: * 18 years old and older * clinic provider plans a transcervical procedure (iud placement or endometrial biopsy) * english speaking and able to consent exclusion criteria: * incarcerated * prior leep (loop electrosurgical excision procedure), cryo (cryotherapy) or ckc (cold knife cone) of the cervix
ican diabetes self-management and prevention program

Conditions: Diabetes Mellitus, Type 2; PreDiabetes

Summary: the purpose of this study is to test the feasibility and preliminary efficacy of the ican diabetes self-management and prevention support group using a single arm clinical trial. the program is composed of six weekly sessions, and it will be implemented with 60 adults (aged 18 years or older) who have been diagnosed with type 2 diabetes or prediabetes and evaluated using mixed methods. a pre-test will be conducted before the program implementation and a post-test will be conducted three months after the pre-test. focus groups will be conducted shortly after the last session to obtain feedback on the program. between the last session and the post-test, weekly emails/texts will be sent to keep participants engaged and maximize retention rate.


Eligibility criteria:
inclusion criteria: * adult aged 18 years or older * have been diagnosed with type 2 diabetes or prediabetes * can read, write, and speak in english exclusion criteria: * attended a diabetes self-management program or diabetes prevention program within the last 3 months * plan to attend another diabetes self-management program or diabetes prevention program within 3 months

Keywords: diabetes mellitus, type 2 prediabetes self-management
hepatocyte growth factor (hgf) concentration in myocardial infarction

Conditions: Acute Coronary Syndrome; Myocardial Infarction

Summary: this is the continuation of previous study (registration number: nct00844987) which revealed that hepatocyte growth factor (hgf) is a very early, good marker of myocardial injury and prognostic factor for post myocardial infarction (mi) cardiovascular events presence in long-term follow-up. due to potentially very important implication of the results of previous study it was decided to continue research of hgf in patients with mi. now, is scheduled to examine 100 consecutive patients with stemi. hgf assessments will be performed just after admission to hospital, 1h and 24h later and before discharge. two follow-up visits were planned i.e. at 3 and 6 months after mi. during hospitalization and at 6 month visit the echocardiography examination will be performed. the composite primary endpoint consists of cardiovascular events observed during hospital course and in long term-follow-up.

hepatocyte growth factor (hgf) was examined in study number nct00844987 as a potentially useful marker of acute myocardial injury. results of the study confirmed efficacy of hgf as very early marker of myocardial necrosis and as a prognostic factor for cardiovascular events in long term follow up. recent study is a continuation of previous study. the aim is to confirm that maximal values of the hgf in first examination performed in acs (acute coronary syndrome) patients and to show predictive value of hgf for early and late outcome in patients with acs. materials and method: 100 patients with acute coronary syndrome will be included into the study. hgf will be examined four times i.e. just after admission, 1h and 24h latter and before discharge. in case of 10 patients will be performed 10 assessments during first day of acs. the follow up visits will take place 3 and 6 months after acs. during hospitalization and 6 months later echocardiography examination will be performed and the extension of heart dysfunction will be assessed. control group will consist of 10-15 health volunteers. the primary endpoint is a composite endpoint which will include following cardiovascular events observed during hospitalization and during 6-month follow up: death, reinfarction, coronary interventions (pci and/or cabg) due to new acs or exacerbation of angina, symptoms of heart failure, rehospitalization due to cardiovascular events and stroke in context of hgf concentration in acute stage of acs. as a secondary endpoints will be considered: 1) death, 2) symptoms of heart failure 3)rehospitalization due to cardiac events observed during hospitalization or in 6-month follow-up. all this endpoints will consider in context of hgf values and values of routinely measured markers of myocardial injury.

Eligibility criteria:
inclusion criteria: * age \>18 years, * chest pain, * symptoms of ischemia at ecg, * signed informed consent form exclusion criteria: * age \< 18 years, * not signed informed consent form.

Keywords: acs, hgf, myocardial infarction markers of myocardial injury acute coronary syndrome (acs) prognostic factors in patients with acs